Cargando…

Under-Represented Populations Left Out of Alzheimer’s Disease Treatment with Aducanumab: Commentary on Ethics

Despite controversy about the efficacy and safety of aducanumab, the FDA’s fast-tracking of this medicine is truly historic. However, structural problems leading to socioeconomic disparities and systemic racism in science, healthcare, and society have left out under-represented populations. This per...

Descripción completa

Detalles Bibliográficos
Autores principales:	Padala, Sanjana P., Yarns, Brandon C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277694/ https://www.ncbi.nlm.nih.gov/pubmed/35891635 http://dx.doi.org/10.3233/ADR-220023

Ejemplares similares

Should Canadian patients look forward to aducanumab for Alzheimer disease?
por: Watt, Jennifer A., et al.
Publicado: (2021)

Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
por: Lalli, Giovanna, et al.
Publicado: (2021)

Aducanumab for Alzheimer’s disease?
por: Walsh, Sebastian, et al.
Publicado: (2021)

Practical Considerations in the Administration of Aducanumab for the Neurologist
por: Coerver, Katherine, et al.
Publicado: (2022)

Commentary: The mitral valve and the left ventricle in functional mitral regurgitation: The puppet and the puppeteer
por: Xu, Dongyang, et al.
Publicado: (2020)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
por: Wojtunik-Kulesza, Karolina, et al.
Publicado: (2023)

Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
por: Vaz, Miguel, et al.
Publicado: (2022)

Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab
por: Chertkow, Howard, et al.
Publicado: (2021)

Mice left out in the cold: commentary on the phenotype of TRPM8-nulls
por: Daniels, Richard L, et al.
Publicado: (2007)

Commentary: Out with the flow
por: Errico, Kristen, et al.
Publicado: (2021)

Commentary: Inside out
por: D'Amico, Thomas A.
Publicado: (2021)

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer’s Disease
por: Abyadeh, Morteza, et al.
Publicado: (2021)

Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
por: Yigit, Vahit, et al.
Publicado: (2023)

Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review
por: Beshir, Semira Abdi, et al.
Publicado: (2022)

Alzheimer disease neuropathology in a patient previously treated with aducanumab
por: Plowey, Edward D., et al.
Publicado: (2022)

Commentary: Simple and effective subvalvular repair for ischemic mitral regurgitation: Yes, we can!
por: Silverman, Michael, et al.
Publicado: (2020)

Aducanumab as a Novel Treatment for Alzheimer’s Disease: A Decade of Hope, Controversies, and the Future
por: Esang, Michael, et al.
Publicado: (2021)

What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?
por: Wallin, Anders, et al.
Publicado: (2022)

Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease
por: Herring, William L., et al.
Publicado: (2021)

Aducanumab for Alzheimer’s disease: The never‐ending story that nurses should know
por: Petch, Joel, et al.
Publicado: (2021)

A Commentary on Jaffe and Hope’s Proposed Ethical Framework
por: Singh, Jerome A.
Publicado: (2010)

Aducanumab: What about the Patient?
por: Petersen, Ronald C.
Publicado: (2021)

Is Aducanumab for LMICs? Promises and Challenges
por: Gunawardena, Illangage P. C., et al.
Publicado: (2021)

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations
por: Cummings, J., et al.
Publicado: (2021)

Commentary: Watch out for WATCHMAN device failures
por: Ward, Alison F., et al.
Publicado: (2020)

Commentary: An ingenious solution born out of necessity
por: Klapper, Jacob A.
Publicado: (2020)

Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price
por: Sinha, Pranay, et al.
Publicado: (2022)

Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer’s Disease
por: Geerts, Hugo, et al.
Publicado: (2021)

Commentary: Targeting the left atrial appendage
por: Gillinov, Marc, et al.
Publicado: (2021)

Commentary: Go out on a limb, that's where the fruit is!
por: Eckhauser, Aaron
Publicado: (2020)

England's new Mental Health Act represents law catching up with science: a commentary on Peter Lepping's ethical analysis of the new mental health legislation in England and Wales
por: Maden, Anthony
Publicado: (2007)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease
por: Zissimopoulos, Julie, et al.
Publicado: (2022)

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease
por: Kandadi Muralidharan, Kumar, et al.
Publicado: (2021)

Erstes kausal wirkendes Medikament gegen Alzheimer?: Die FDA lässt Aducanumab zu
por: Hager, Klaus
Publicado: (2021)

Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
por: Lin, Lin, et al.
Publicado: (2022)

THE ETHICS OF AN OPT-OUT DEFAULT IN TOBACCO TREATMENT
por: Ashcroft, Richard E
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h01kbt5bnc55op5gbt4t5bjttu